1. "Center for Pancreatic Cancer Research"
Formats
  1. Journal Article (4996)
  2. Meeting Abstract (2461)
  3. Book Section (214)
  4. Review (209)
  5. Editorial (129)
  6. Conference Paper (75)
  7. Correspondence (46)
  8. Research Letter (40)
  9. Miscellaneous (39)
  10. Guidelines (36)
  11. Book Whole (19)
Groups
  1. Center for Pancreatic Cancer Research (8264)
  2. Department of Medicine (3883)
  3. Solid Tumor Oncology Division (3194)
  4. Surgery (3115)
  5. GSK Faculty (2868)
  6. Epidemiology and Biostatistics (2495)

More Groups

People
  1. Mithat Gonen (1028)
  2. William Jarnagin (903)
  3. Eileen O'Reilly (780)
  4. Michael D'Angelica (777)
  5. T Peter Kingham (609)
  6. David Kelsen (537)

More People

Years
  1. 2025 (184)
  2. 2024 (487)
  3. 2023 (522)
  4. 2022 (602)
  5. 2021 (555)
  6. 2020 (555)

More Years

Publications
  1. Journal of Clinical Oncology (917)
  2. Annals of Surgical Oncology (389)
  3. Cancer Research (225)
  4. International Journal of Radiation Oncology, Biology, Physics (219)
  5. Laboratory Investigation (206)
  6. Modern Pathology (191)

More Publications

Publishers
  1. American Society of Clinical Oncology (986)
  2. Springer (831)
  3. Elsevier Inc. (810)
  4. Nature Publishing Group (623)
  5. American Association for Cancer Research (546)
  6. Elsevier Science, Inc. (504)

More Publishers

Results (8264)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Risk of radiation-associated secondary malignancies among patients with breast cancer harboring TP53 germline variants
    Meeting Abstract

    Cederquist, G.; Boe, L.; Walsh, M. F.; Stadler, Z.; Xu, A. J.; Mueller, B. A.; Roth O'Brien, D. A.; Bernstein, M. B.; Cuaron, J.; Bakhoum, S. F.; more...
    International Journal of Radiation Oncology, Biology, Physics (2023)

    Fulltext@MSK | Save
  • Nomogram to predict risk of early mortality following definitive or adjuvant radiation and systemic therapy for head and neck cancer
    Meeting Abstract

    Raab, G. T.; Yu, Y.; Sherman, E.; Wong, R. J.; Mell, L. K.; Lee, N. Y.; Zakeri, K.
    International Journal of Radiation Oncology, Biology, Physics (2023)

    Fulltext@MSK | Save
  • Favorable survival after definitive ablative RT in surgically resectable pancreatic cancer patients
    Meeting Abstract

    Reyngold, M.; O'Reilly, E.; Zinovoy, M.; Hajj, C.; Wu, A. J.; Cuaron, J.; Romesser, P.; Varghese, A. M.; Park, W.; Yu, K.; more...
    International Journal of Radiation Oncology, Biology, Physics (2023)

    Fulltext@MSK | Save
  • PD-1 blockade as curative intent therapy in mismatch repair deficient locally advanced rectal cancer
    Meeting Abstract

    Cercek, A.; Lumish, M.; Sinopoli, J.; Weiss, J.; Shia, J.; Stadler, Z.; Yaeger, R.; Smith, J. J.; Saltz, L.; Widmar, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET)
    Meeting Abstract

    Chan, J.; Geyer, S.; Ou, F. S.; Knopp, M.; Behr, S.; Zemla, T.; Acoba, J.; Shergill, A.; Wolin, E. M.; Halfdanarson, T. R.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study
    Meeting Abstract

    Shiu, K. K.; André, T.; Kim, T. W.; Vittrup Jensen, B.; Jensen, L. H.; Punt, C. J. A.; Smith, D.; Garcia-Carbonero, R.; Alcaide-Garcia, J.; Gibbs, P.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Chemotherapy priming leads to hypermutability and immune surveillance in colorectal cancer
    Meeting Abstract

    Vitiello, P. P.; Chilà, R.; Battuello, P.; Battaglieri, V.; Amodio, V.; Grasso, G.; Rospo, G.; Lamba, S.; Pisati, F.; Rousseau, B. J. C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
    Meeting Abstract

    Schram, A.; Macarulla, T.; Cleary, J.; Neuzillet, C.; Arnold, D.; Reiss, K. A.; Bekaii-Saab, T.; Rodon, J.; Goto, K.; Rha, S. Y.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • A novel endoscopic ultrasound guided extended-release siRNA implant targeting KRASG12D/V in localized pancreatic cancer
    Meeting Abstract

    Varghese, A. M.; Golan, T.; Schattner, M.; Ang, C.; Gutierrez, M.; Passhak, M.; Geva, R.; Yarom, N.; Ligresti, R.; Khamaysi, I.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Health-related quality of life with nalirifox versus nabpaclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): EORTC QLQ-C30 results from the NAPOLI 3 trial
    Meeting Abstract

    Melisi, D.; Macarulla, T.; de la Fouchardiere, C.; Cid, R. A. P.; Chandana, S.; Dean, A.; Kiss, I.; Lee, W.; Goetze, T. O.; Van Cutsem, E.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save